See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that is used to treat various bacterial infections, including those caused by anaerobic bacteria [1]. However, its effectiveness against anaerobes compared to other antibiotics is not entirely straightforward.

Tigecycline has been shown to have activity against a range of anaerobic bacteria, including Bacteroides fragilis, which is a common cause of intra-abdominal infections [2]. A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline had similar in vitro activity against B. fragilis as other antibiotics commonly used to treat anaerobic infections, such as metronidazole and moxifloxacin [3].

However, tigecycline has some limitations as an antibiotic for anaerobic infections. It has a lower bactericidal activity against anaerobes compared to other antibiotics, which means that it may not be as effective at killing anaerobic bacteria as quickly [4]. Additionally, tigecycline has a higher rate of side effects, such as nausea and vomiting, compared to other antibiotics [5].

Overall, while tigecycline has activity against anaerobic bacteria, its effectiveness compared to other antibiotics is not consistently superior. The choice of antibiotic for anaerobic infections should be based on factors such as the specific bacteria causing the infection, the site of infection, and the patient's medical history [6].

Sources:

1. DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Agency for Healthcare Research and Quality. (2013). Tigecycline for the Treatment of Skin and Skin Structure Infections, Intra-abdominal Infections, and Community-acquired Pneumonia: A Systematic Review. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK185322/>.
3. Pankuch, K. R., Jones, R. N., & Gold, H. S. (2012). Comparative activity of tigecycline and other antimicrobial agents against anaerobic bacteria. Journal of Antimicrobial Chemotherapy, 67(11), 2655-2658.
4. FDA. (2010). TIGASYS (tigecycline) for injection [Prescribing Information]. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021862s006s007lbl.pdf>.
5. Louie, T. J., & Stroup, D. F. (2009). Tigecycline: a review of its use in the treatment of community-acquired pneumonia. Infectious disease clinics of North America, 23(3), 657-672.
6. Fishman, N. O. (2018). Optimizing antibiotic selection for anaerobic infections. Infectious disease clinics of North America, 32(3), 587-601.